John Maraganore on his new biotech venture, R&D vivacity and Nobel award-winning AI

Taking stock of the drug industry, from the lab to the medicine chest

October 11, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Keith Bedford/The Boston Globe STAT+ | John Maraganore on his new biotech venture, R&D vivacity and Nobel award-winning AI The former CEO of Alnylam spoke with STAT about raising money to focus on one big idea, and the prospect for a $100 billion Alnylam. By Allison DeAngelis and Adam Feuerstein As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle The FDA's warning to compounders threatens access to cheaper versions of Zepbound and Lilly's diabetes medicine Mounjaro. By Elaine Chen STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Adobe STAT+ | Teva agrees to pay $450 million to settle kickback and price-fixing allegations Teva also agreed to pay $25 million to resolve allegations it conspired with other generic drug companies to fix prices for three drugs. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser